BA: University of Guelph, S.Sc. Hon, Molecular Biology and Genetics Guelph, Ontario, Canada 1992.
PhD: University of Toronto, PhD Department of Laboratory Medicine Toronto, Ontario, Canada 1999.
Fellowship: Childrens Hospital Los Angeles Department of Pediatrics Division of Research Immunology/BMT Los Angeles, CA, 1999-2002.
Regulating human pluripotent stem cell; somatic cell reprogramming in iPSC; human embryonic stem cell physiology and differentiation; hESC; cystic fibrosis
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases
Integrated Genomic Analysis of Diverse Induced Pluripotent Stem Cells from the Progenitor Cell Biology Consortium. Stem Cell Reports. 2016; 7:110-125.
Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. The Journal of Clinical Investigation. 2015; 125:3103-3116.
A toxicology study of Csf2ra complementation and pulmonary macrophage transplantation therapy of hereditary PAP in mice. Molecular Therapy-Methods & Clinical Development. 2024; 32:101213.
CMV SEROSTATUS IS MOST IMPORTANT TO SELECT DONORS OF MONONUCLEAR CELL PRODUCTS AIMED TO THE GENERATION OF ANTI-CMV VIRUS-SPECIFIC T CELL (VSTS) PRODUCTS. Cytotherapy (Informa). 2024; 26:e20-e21.
Erythrocyte Disorders Mimicking Congenital Dyserythropoietic Anemia Based on Bone Marrow Pathology Exposed By Genetic Evaluation. Blood. 2023; 142:2459.
Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Transplantation and Cellular Therapy. 2023; 29:305-310.
De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts. Blood. 2022; 140:1234-1235.
Successful Ex Vivo Telomere Elongation with Exg-001 in a Patient with a Dyskeratosis Congenita. Blood. 2022; 140:1895-1896.
Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant. Blood Advances. 2022; 6:2897-2907.
477 Availability of Donor Derived Patient Specific Virus-Specific T-Cells (VSTs) Is Not Associated with Differences in Outcomes As Compared to Frontline Administration of Third Party Vsts for the Management of Viral Infections after Pediatric Hematopoietic Stem Cell Transplant. Transplantation and Cellular Therapy. 2022; 28:s374-s375.
Carolyn M. Lutzko, PhD4/2/2020